Replimune Group Inc (REPL)
🔔 Watch stock
symbol.quality_heading
We found at least one documented issue that threatens the company itself — regardless of how the stock is currently valued.
The auditor's going-concern note and the cash "only into Q1 2027" are hard warning signals, as are Altman Z deep in the red and Piotroski 1 of 9. At the same time the case is binary: an RP1 approval around August 2, 2026 could lever the slim market value upward, a third no would hit a company at its cash limit. Abrupt price moves in both directions are possible around this date. The decision is yours.
symbol.quality_note
Replimune builds viruses meant to blow tumors open from the inside — one of the most exciting ideas in cancer medicine. Only, the company earns not a single dollar from it so far. The stock shows up in our going-concern warning scanner, and its own annual report confirms exactly that: we read the 10-K for fiscal year 2026 and the quarterly report (10-Q) — $1.26 billion in accumulated losses, a till that per the auditor lasts only into early 2027, an explicit doubt about survival, and two FDA rejections for the cancer therapy RP1. Still the price jumped 153 percent in two months. Not investment advice — just a sober cash count before the big date.
Read the analysis
Stock Watch
This analysis is as of July 15, 2026. Stock Watch will tell you what's changed at REPL since then.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 11.20 $ — 96% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
NeutralGeprüft am 13.07.2026 gegen die Geschäftsberichte (10-K) für die Geschäftsjahre bis 31.03.2026 (eingereicht 29.06.2026) und bis 31.03.2025 (22.05.2025) sowie die vier jüngsten Quartalsberichte (10-Q). Replimune ist ein klinisches Biotech-Unternehmen für onkolytische Immuntherapie (RPx-Plattform auf HSV-1-Basis; Leitwirkstoff RP1 gegen fortgeschrittenes Melanom). In den ausgewerteten SEC-Filings findet sich kein wesentlicher KI-Bezug: keine KI-Produkte oder -Dienste als Umsatzquelle (das Unternehmen erzielt überhaupt keinen Produktumsatz), kein dokumentierter operativer KI-Einsatz (etwa in der Wirkstoff-Forschung) und kein konkretes KI-Geschäftsrisiko fürs eigene Modell. Die einzigen zwei Erwähnungen von „artificial intelligence“ im 10-K 2026 sind eine generische regulatorische Sammel-Floskel, die KI zusammen mit Datenschutz und Cybersicherheit als mögliche künftige EU-Compliance-Anforderung nennt (EU-KI-Verordnung) — nach dem Kriterienkatalog ist das eine Boilerplate-Risk-Floskel ohne konkreten Bezug zum onkolytischen Virus-Geschäft und begründet weder „bedroht“ noch „nutzt“ noch „verkauft“. Damit bleibt es beim dokumentierten Negativ-Befund „neutral“.
View the full file — quotes, sources, reviewed filings
„We may also be subject to additional industry-specific privacy, cybersecurity, data protection, operational and information systems resilience, and artificial intelligence-related laws in Europe (including the EU AI Act) which may subject us to additional similar risks and impacts."
Wir könnten zudem zusätzlichen branchenspezifischen Vorschriften in Europa zu Datenschutz, Cybersicherheit, operativer und informationssystembezogener Widerstandsfähigkeit sowie zu künstlicher Intelligenz (einschließlich der EU-KI-Verordnung) unterliegen, die uns ähnlichen zusätzlichen Risiken und Auswirkungen aussetzen können.
„We are a clinical-stage biotechnology company committed to applying our leading expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through our novel oncolytic immunotherapies."
Wir sind ein Biotech-Unternehmen im klinischen Stadium, das seine führende Expertise auf dem Gebiet der onkolytischen Immuntherapie einsetzt, um das Leben von Krebspatienten durch unsere neuartigen onkolytischen Immuntherapien zu verändern.
Filings Reviewed: 10-K 2026-06-29 · 10-K 2025-05-22 · 10-Q 2026-02-03 · 10-Q 2025-11-06 · 10-Q 2025-08-07 · 10-Q 2025-02-12
Rated on July 13, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 7.1% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 8
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 03/31/2027 | -2.14 | -2.52 – -1.93 | 49 | 36.6% | 3 |
| 03/31/2028 | -1.27 | -1.55 – -1.04 | 103 | 40.6% | 3 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.66 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q3 | -0.68 | – | 0 | – | – | -39 | -41 |
| 2024: Q4 | -0.79 | – | 0 | – | – | -51 | -53 |
| 2025: Q1 | -0.92 | – | 2 | -63.60 | -5,036.00 | -54 | -55 |
| 2025: Q2 | -0.95 | – | 0 | – | – | -77 | -80 |
| 2025: Q3 | -0.90 | – | 0 | – | – | -81 | -83 |
| 2025: Q4 | -0.77 | – | 0 | – | – | -66 | -66 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2017 | 0 | -10 | -8 | -0.25 | -7 | -12 | 23 |
| 2018 | 0 | -19 | -20 | -0.64 | -16 | -28 | 65 |
| 2019 | 0 | -31 | -31 | -1.33 | -25 | 138 | 154 |
| 2020 | 0 | -56 | -53 | -1.54 | -61 | 184 | 234 |
| 2021 | 0 | -83 | -81 | -1.75 | -61 | 499 | 543 |
| 2022 | 0 | -121 | -118 | -2.26 | -82 | 411 | 461 |
| 2023 | 0 | -177 | -174 | -2.99 | -128 | 555 | 647 |
| 2024 | 0 | -235 | -216 | -3.24 | -185 | 375 | 488 |
| 2025 | 0 | -262 | -247 | -3.07 | -192 | 416 | 551 |
| 2026 | 0 | -320 | -314 | -3.38 | -280 | 166 | 332 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Assessment: Opportunities & Risks
Oncolytic immunotherapy on its own RPx platform (HSV-1) is one of the most exciting ideas in cancer medicine; the lead drug RP1 is tested in the IGNYTE trial against advanced melanoma, combined with nivolumab, which Bristol Myers Squibb contributes free of charge (annual report 10-K 2026).
The auditor has issued a going-concern note: the cash ($268.9 million as of March 31, 2026) lasts, per the company, only into the first calendar quarter of 2027, against an operating cash outflow of $280.3 million in fiscal year 2026 and with no committed further financing.
No product revenue since inception; the net loss rose in three fiscal years from $66.6 to $313.9 million, the accumulated deficit stands at $1,262.5 million — more than the entire market weight. The stock's value is entirely a bet on a future approval.
Two rejection notices (CRL) in July 2025 and April 2026 — the second contradicted, per the company, an earlier FDA position. On June 26, 2026 the FDA accepted the resubmission with an action date of August 2, 2026 and an advisory committee in late July 2026: a binary event with an open outcome.
Plus 153 percent in two months and plus 642 percent above the 52-week low, carried by the approval hope; about 97 percent institutional ownership. At the same time technical scanners rate the rally as a topping formation (Weinstein Stage 3) and "overheated" — an altitude rush next to a going-concern note.
Replimune is not a case of substance versus story, but a pure bet with clear conditions: a fascinating cancer technology and a tangible FDA date of August 2, 2026 on one side — on the other an auditor who doubts survival in black and white, not a cent of revenue, $1.26 billion in accumulated losses, two regulatory rejections and a workforce cut of about 55 percent. The stock is a warrant on a single yes or no. Not investment advice.
- Replimune's fiscal year ends on March 31; annual figures refer to the respective fiscal year (e.g. "2026" = April 1, 2025 through March 31, 2026). Program and trial milestones, by contrast, the company reports on a calendar-year basis.
- All earnings and balance-sheet figures come from the audited annual report 10-K for the fiscal year ended March 31, 2026 as well as the quarterly reports; the FDA date status (August 2, 2026) is the status stated in the 10-K.
- Price and valuation figures dated to July 8, 2026 (about $11); analyses are evergreen, daily prices are not a buy argument.
About the Company
Replimune Group, Inc., ein Biotechnologieunternehmen in der klinischen Phase, konzentriert sich auf die Entwicklung und Vermarktung onkolytischer Immuntherapien zur Krebsbehandlung.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 465 |
| Headquarters | Woburn, MA |
| Address | 500 Unicorn Park Drive, 01801 Woburn, United States |
| Phone | 781 222 9600 |
| Website | replimune.com |
| IPO Date | 20. Jul 2018 |
| ISIN | US76029N1063 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Sushil Patel Ph.D. | CEO & Director | 1971 |
| Emily Luisa Hill | Chief Financial Officer | 1980 |
| Konstantinos Xynos M.B.A., M.D., Ph.D. | Chief Medical Officer | 1966 |
| Philip Astley-Sparke F.S.A. | Executive Chairman | 1971 |
| Andrew Schwendenman | Chief Accounting Officer & Treasurer | 1976 |
| Shawn Glidden J.D. | Senior VP & General Counsel | – |
| Camilo Garcia M.A., M.B.A. | Chief Human Resource Officer | – |
| Paul Bullock | Chief Manufacturing Officer & Framingham Site Head | – |
| Nina Aragam | Senior Vice President of Portfolio Strategy & Program Management | – |
| Carolyn Trott | Senior Vice President of Quality Assurance | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.